Surrozen pauses Phase I trial following liver enzyme elevationsR&D, TherapeuticsSurrozen announced it paused its Phase I study Crohn’s disease and ulcerative colitis as several healthy participants showed increased levels of liver enzymes. Read more November 15, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/06/BioSpacedoctor6-30-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-11-15 10:33:022022-11-15 10:33:02Surrozen pauses Phase I trial following liver enzyme elevations
